医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BSD Medical Announces First Symposium on Hyperthermia Treatment of Cancer in Taiwan to Feature BSD-2000 Hyperthermia System

2013年10月30日 PM10:40
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company’s BSD-2000 Hyperthermia System (BSD-2000) will be featured at the first symposium on hyperthermia treatment of cancer held in Taiwan. Taipei Medical University and Taipei City Wan Fang Hospital will jointly host the “2013 Taipei International Symposium on Cancer Hyperthermia” on Sunday, November 3, at the Taipei Medical University. BSD’s exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden), has been invited to present on the BSD-2000 at the symposium.

The conference will feature presentations by pre-eminent hyperthermia researchers, including Dr. Jacobi van der Zee, a world recognized authority on hyperthermia treatment. BSD’s equipment will be featured in many of these presentations. Eight of the cancer-related societies in Taiwan will participate in the symposium. Many physicians throughout Taiwan and Asia do their internships at Wan Fang Hospital because the hospital is affiliated with Taipei Medical University.

Linden has committed to purchasing four (4) BSD-2000 Hyperthermia Systems. Shipment of the hyperthermia systems ordered will commence with Linden’s receipt of Taiwan Food and Drug Administration (TFDA) import license approval, which is in process.

“We are excited about the opportunity to showcase the BSD-2000 Hyperthermia System at the upcoming symposium,” stated Dr. Tainang Huang, President of Linden. “We have already met with prominent Taiwan physicians from several hospitals. We are excited about the potential market for the BSD-2000 in Taiwan, which is one of the most advanced medical device markets in Asia.”

Taiwan has a strong healthcare system, and the universal health insurance ensures that all citizens have grown to expect a high level of care. Taiwan’s medical device market is approximately $1.6 billion.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical’s website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.

.

CONTACT

BSD Medical Corporation
William Barth, 801-972-5555
investor@bsdmc.com
fax:
801-972-5930

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent